Convergence Investment Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Convergence Investment Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.04M	Buy	164,314 +17,884	+12%	+$240K	0.33%	104
2025 Q4	$1.85M	Buy	146,430 +49,513	+51%	+$567K	0.37%	90
2025 Q3	$970K	Sell	96,917 -62,852	-39%	-$564K	0.22%	163
2025 Q2	$1.29M	Buy	159,769 +4,650	+3%	+$35.1K	0.33%	106
2025 Q1	$1.3M	Sell	155,119 -52,890	-25%	-$441K	0.36%	92
2024 Q4	$1.65M	Buy	208,009 +41,161	+25%	+$345K	0.37%	97
2024 Q3	$1.39M	Buy	166,848 +23,633	+17%	+$185K	0.37%	89
2024 Q2	$909K	Buy	+143,215	New	+$909K	0.27%	121

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Convergence Investment Partners's AMRX Position: Q1 2026 in Review

Convergence Investment Partners increased its Amneal Pharmaceuticals (AMRX) stake by 12% in Q1 2026, buying an estimated $240K and bringing the position to 164,314 shares worth $2.04M. The position accounts for 0.33% of the portfolio, ranked #104.

Convergence Investment Partners first reported a position in AMRX in Q2 2024 and has held it in 8 quarters since. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Convergence Investment Partners held 164,314 shares of Amneal Pharmaceuticals worth $2.04M as of Q1 2026.
Convergence Investment Partners bought 17,884 Amneal Pharmaceuticals shares in Q1 2026, an estimated $240K.
Amneal Pharmaceuticals made up 0.33% of Convergence Investment Partners's portfolio in Q1 2026, its #104 holding.
Convergence Investment Partners first reported a position in Amneal Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Convergence Investment Partners's 13F filing for Q1 2026, filed 7 May 2026.